Eli Lilly has agreed to a deal worth up to $1.3 billion with Superluminal Medicines to use its AI platform for discovering obesity and cardiometabolic drugs.
Lilly, already a leader in the booming obesity treatment market, will gain exclusive rights to develop and commercialize drug candidates found using Superluminal’s technology. The platform is designed to rapidly identify promising compounds, potentially accelerating the path to clinical trials.
Superluminal’s lead candidate, targeting rare genetic obesity, is slated for human trials next year. The agreement includes upfront and milestone payments, an equity investment, and tiered royalties.
The deal bolsters Lilly’s push to maintain its edge through partnerships, acquisitions and next-generation drug development.
